Navigation Links
Helix BioPharma Chairman resigns
Date:10/15/2007

AURORA, ON, Oct. 15 /PRNewswire-FirstCall/ - Helix BioPharma Corp. (TSX: HBP / Frankfurt: WKN 918864) announced today that Jerome F. McElroy has resigned as Chairman and a director of the Company to pursue his retirement interests.

"Jerry has had a long involvement with the Company since its amalgamation in 1995," said Don Segal, President and Chief Executive Officer. "On behalf of the Company, I thank him for his positive contributions and wish him well with his future endeavors."

The Company has entered into an agreement with Mr. McElroy in respect of his resignation, pursuant to which Mr. McElroy will receive the equivalent of approximately one year's salary and benefits in a lump sum payment made today of $350,000, plus termination payments for one year of $3,000 per month and contributions to his medical benefits of $12,000 per year for four years.

The Company will designate a new Chairman to succeed Mr. McElroy in the near term.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its Topical Interferon Alpha-2b, for the treatment of conditions caused by the human papilloma virus, and its novel L-DOS47 new drug product candidate for the treatment of lung adenocarcinoma. Helix is listed on the Toronto Stock Exchange under the ticker symbol "HBP".

This News Release contains certain forward-looking statements and information regarding Helix's product development initiatives, Topical Interferon Alpha-2b and L-DOS47. Forward-looking statements and information can be identified by the use of forward-looking terminology such as "developing" and "initiatives". Helix's actual results could differ materially from those anticipated in these forward-looking statements and information as a result of numerous factors, including without limitation, Helix's need for additional capital in the near term and in future, which may not be available on acceptable terms or at all; and uncertainty whether Topical Interferon Alpha-2b, L-DOS47, or any other product will be developed and marketed successfully as a drug or at all. See a description of other risks and uncertainties affecting Helix and its business, as contained in Helix's latest Annual Information Form and other filings with the Canadian Securities Regulatory Authorities at http://www.sedar.com, any of which could cause actual results to vary materially from current results or Helix's anticipated future results. Forward-looking statements and information are based on the beliefs, opinions and expectations of Helix's management at the time they are made, and Helix does not assume any obligation, except as required by law, to update any forward-looking statement or information should those beliefs, opinions or expectations, or other circumstances change.


'/>"/>
SOURCE Helix BioPharma Corp.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Kyron appoints former AMA chairman to board
2. Third Wave appoints new chairman
3. Cisco Chairman donates $31 million for UW building renovation
4. Bone Care Names New Chairman
5. Cisco Chairman Praises University Research
6. JT Packard exec resigns after settling copyright disputes
7. Donley resigns as WiCell director
8. Renaissance Learning CEO resigns to start company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... BD (Becton, Dickinson and Company) (NYSE: BDX ), a ... live webcast of its Annual Meeting of Shareholders on Tuesday, January ... can be accessed from the BD corporate website at http://www.bd.com/investors/ ... ... BD is a global medical technology company that is ...
(Date:1/18/2017)... , Jan. 18, 2017   Boston Biomedical ... compounds designed to target cancer stemness pathways, will feature ... compound, napabucasin, at the 2017 ASCO Gastrointestinal Cancers Symposium, ... . Napabucasin is an orally-administered ... targeting STAT3. i Cancer stem cells (CSCs) possess ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... ... for Clinical Ops Executives 2017 in its continued commitment to the advancement of ... makers to discuss current issues related to clinical trial planning and management. ...
(Date:1/18/2017)... ... January 18, 2017 , ... Announced in December ... Institutes (MII). U.S. Secretary of Commerce Penny Pritzker has announced the award of ... of Defense has announced the award of a new Advanced Regenerative Manufacturing Institute ...
Breaking Biology Technology:
(Date:12/16/2016)... Research and Markets has announced the addition of the ... report to their offering. ... The biometric vehicle access system market, in terms of ... 2016 to 2021. The market is estimated to be USD 442.7 ... 2021. The growth of the biometric vehicle access system market is ...
(Date:12/15/2016)... , Dec. 15, 2016   WaferGen Bio-systems, Inc. ... genomics technology company, announced today that on December 13, ... Department of The Nasdaq Stock Market LLC which acknowledged ... price of WaferGen,s common stock had been at $1.00 ... has regained compliance with Listing Rule 5550(a)(2) of the ...
(Date:12/15/2016)... AUBURN HILLS, Mich. , Dec. 15, 2016 /PRNewswire/ ... simply unlocking car doors or starting the engine. Continental ... 2017 in Las Vegas . Through ... PASE (Passive Start and Entry) and biometric elements, the ... the field of vehicle personalization and authentication. ...
Breaking Biology News(10 mins):